Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
...
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05065047
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT05060627
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Germans Trias i Pujol (ICO BADALONA), Badalona, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
A Phase 1 with Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05055063
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 24
- Registration Number
- NCT05002816
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04876248
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 66
- Registration Number
- NCT04808037
- Locations
- 🇬🇷
General Hospital of Athens "Alexandra", Athens, Attica, Greece
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 50
- Registration Number
- NCT04802356
- Locations
- 🇪🇸
Hospital Gregorio Marañon, Madrid, Comunidad Autónoma De Madrid, Spain
🇪🇸Institut Catala d'Oncologia (ICO) Hospitalet, Hospitalet de Llobregat, Cataluña, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 47
- Registration Number
- NCT04680468
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Jacob Soumerai, MD
- Target Recruit Count
- 25
- Registration Number
- NCT04676360
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷Investigational Site Number : 2500002, Lille, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.